Press coverage about Aralez Pharmaceuticals (NASDAQ:ARLZ) has been trending somewhat negative on Friday, Accern Sentiment reports. The research group rates the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aralez Pharmaceuticals earned a coverage optimism score of -0.02 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.7162526372445 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Aralez Pharmaceuticals (NASDAQ:ARLZ) traded up $0.28 during mid-day trading on Friday, reaching $1.96. The company had a trading volume of 2,280,900 shares, compared to its average volume of 759,400. The company has a current ratio of 1.00, a quick ratio of 0.92 and a debt-to-equity ratio of 4.64. Aralez Pharmaceuticals has a 12 month low of $0.95 and a 12 month high of $4.66. The firm has a market cap of $112.37, a PE ratio of -1.16 and a beta of 1.37.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.39) by $0.02. Aralez Pharmaceuticals had a negative return on equity of 118.13% and a negative net margin of 112.89%. The company had revenue of $24.30 million for the quarter, compared to analysts’ expectations of $22.87 million. During the same period in the previous year, the firm posted ($0.32) EPS. Aralez Pharmaceuticals’s revenue was up 78.7% compared to the same quarter last year. equities research analysts anticipate that Aralez Pharmaceuticals will post -1.54 earnings per share for the current fiscal year.
In other news, Director Arthur S. Kirsch acquired 50,000 shares of the stock in a transaction that occurred on Friday, December 8th. The shares were bought at an average cost of $1.47 per share, for a total transaction of $73,500.00. Following the acquisition, the director now owns 271,609 shares in the company, valued at approximately $399,265.23. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 6.70% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Somewhat Critical Press Coverage Somewhat Unlikely to Affect Aralez Pharmaceuticals (ARLZ) Share Price” was first reported by TrueBlueTribune and is the property of of TrueBlueTribune. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.truebluetribune.com/2018/01/19/somewhat-critical-press-coverage-somewhat-unlikely-to-affect-aralez-pharmaceuticals-arlz-share-price.html.
Aralez Pharmaceuticals Company Profile
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Receive News & Ratings for Aralez Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.